SB 202190

SKU: orb1226157

Description

SB 202190 (SB202190, SB-202190) is a potent inhibitor p38α and p38β with IC50 of 50 nM and 100 nM respectively; stimulates the activity of CPP32-like caspases, potentiates apoptosis induced by Fas(APO-1) ligation or UV irradiation.(In Vitro):SB 202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner.SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480).In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling.(In Vivo):SB 202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth.

Key Properties

• CAS Number: 152121-30-7
• MW: 331.343
• Purity: >98% (HPLC)
• Formula: C₂₀H₁₄FN₃O
• SMILES: OC1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1
• Target: p38 MAPK
• Solubility: DMSO: ≥ 40 mg/mL

Bioactivity

• In Vivo:
  Animal model: 4-week-old female BALB/c nude mice (bearing SW480 and RKO xenograft tumors). Dosage: 5 mg/kg. Administration: Intraperitoneal injection; daily for 10-12 days. Result: Inhibition of tumor cell survival and tumor growth.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SB202190 | SB-202190

Quick Database Links

Gene Symbol

p38 MAPK